Cheryl Black
Endocrinology, Diabetes & Metabolism · Oklahoma City, OKNPI 1447322680
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,580 of the $8,462 with a category attached, or 89.6%. It is spread thinly across 34 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,080 and has fallen 94.5% since, to $169 in 2023.
Across 465 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novo Nordisk$851
- Amgen$848
- AstraZeneca$727
- Abbott$618
- Boehringer Ingelheim$562
- plus $4K from 28 others
What the payments were for
- Travel & lodging$88310%
- Food & beverage$7,58090%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 17 | $1,140 |
| Novo Nordisk | 52 | $851 |
| Amgen | 55 | $848 |
| AstraZeneca | 40 | $727 |
| Abbott | 28 | $618 |
| Boehringer Ingelheim | 38 | $562 |
| Lilly USA, LLC | 28 | $459 |
| Corcept Therapeutics | 21 | $410 |
| Tandem Diabetes Care, Inc. | 21 | $375 |
| Mannkind Corporation | 23 | $349 |
| Xeris Pharmaceuticals, Inc. | 18 | $264 |
| AbbVie(2 entities) | 15 | $259 |
| Bayer | 18 | $243 |
| Dexcom, Inc. | 13 | $221 |
| Amarin Pharma, Inc. | 16 | $191 |
| Insulet Corporation | 13 | $189 |
| Sanofi-aventis U.S. LLC | 9 | $143 |
| Radius Health, Inc. | 7 | $117 |
| Kowa Pharmaceuticals America, Inc. | 4 | $68 |
| IBSA Pharma Inc. | 4 | $61 |
| Shire North American Group Inc | 3 | $47 |
| Johnson & Johnson | 3 | $45 |
| Endo Pharmaceuticals Inc. | 3 | $42 |
| Merck | 3 | $41 |
| Nestle Healthcare Nutrition Inc. | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| W. L. Gore & Associates, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Zealand Pharma US, Inc. | 1 | $12 |
| Amryt Pharma Holdings Ltd | 1 | $12 |
| Aegerion Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$838
- FreeStyle Libre 2$133
- Enlite Sensor$106
- FARXIGA$104
How this compares
$8,462 in reported general payments places this provider in the 75th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Other endocrinology, diabetes & metabolism in Oklahoma City
- Christian MangrumOklahoma City$54K
- Robert ScofieldOklahoma City$15K
- Donny WynnOklahoma City$11K
- Diana KennedyOklahoma City$8K
- Ali TipuOklahoma City$8K
- Amanda LagrecaOklahoma City$7K
- Bassam ArodakOklahoma City$6K
- Myrto EliadesOklahoma City$5K
- Hamsa AljumailiOklahoma City$5K
- Modhi GudeOklahoma City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.